Drug Trial Radar · NCT07331818
Luspatercept in Patients Affected With Rare Inherited Anemias
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Mar 17, 2026
Primary completion
Sep 2028
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- EuroBloodNet AssociationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective multicenter phase II basket trial evaluating Luspatercept in patients affected with rare inherited anemias
Conditions
- Hereditary Red Blood Cell Disorder (Disorder)
Interventions
ReblozylDrug
Reblozyl 25 mg powder for solution for injection / Reblozyl 75 mg powder for solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluating Luspatercept in patients affected with rare inherited anemias - Transfusion dependent patientsTime frame: Up to 52 weeks
- Evaluating Luspatercept in patients affected with rare inherited anemias - Non Transfusion dependent patientsTime frame: Up to 52 weeks
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
GCS Groupement des Hôpitaux de l'Institut Catholique de Lille
Lille, France · Recruiting
Centre Hospitalier Universitaire de Montpellier
Montpellier, France · Recruiting
Assistance Publique Hôpitaux de Paris - Hôpital Saint-Louis
Paris, France · Recruiting
Assistance Publique Hôpitaux de Paris - Hôpital Necker
Paris, France · Recruiting
CHU Bordeaux-Hôpital Haut-Lévêque
Pessac, France · Recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, Italy · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.